Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC/Q-TOF
نویسنده
چکیده
In this paper, we are investigating an antibody drug conjugate (ADC) with a cysteine linker. The Agilent 1290 Infinity II liquid chromatography system connected to a PLRP-S reversed phase liquid chromatography column was used to separate restored light and heavy chains and light and heavy chains of the corresponding drug linkers. Each chromatographic peak was verified through the Agilent 6530 High-resolution quadrupole time of flight (Q-TOF) LC-MS system. The peak area percentage of each light and heavy chain in the UV absorption spectrum was integrated and combined with the number of drug conjugates corresponding to each peak, and the weighted average drug to antibody ratio (DAR) was calculated for ADC. The Agilent DAR Calculator was used to calculate the DAR values for the mass spectral deconvolution data at mean time, and the results were the same as the UV absorption spectrum calculations.
منابع مشابه
MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates
Background: It is believed that the loading value of anticancer drug conjugated to the monoclonal antibody, called drug-to-antibody ratio (DAR), is the main quality feature of antibody-drug conjugates. Methods: In this study, matrix assisted laser desorption/ionization mass spectrometry was used to determine the average molecular weight of trastuzumab and its three conjugated forms. The differe...
متن کاملEvaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, ...
متن کاملIn Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
Antibody drug conjugates (ADCs) are monoclonal antibodies designed to deliver a cytotoxic drug selectively to antigen expressing cells. Several components of an ADC including the selection of the antibody, the linker, the cytotoxic drug payload and the site of attachment used to attach the drug to the antibody are critical to the activity and development of the ADC. The cytotoxic drugs or paylo...
متن کاملNext generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging† †Electronic supplementary information (ESI) available: Synthetic procedures, 1H and 13C NMR spectra for synthesised compounds, additional SDS-PAGE gels, LCMS chromatograms, Ellman's analysis and other supplementary results. See DOI: 10.1039/c4ob01550a Click here for additional data file.
The advent of Adcetris™ and Kadcyla™, two recently FDA-approved antibody-drug conjugates (ADCs), in the clinic has had a major impact on the treatment of lymphoma and breast cancer patients, respectively, worldwide. Despite these successes many new ADCs fail at various stages of development, often due to shortcomings in the methods used for their assembly. To address this problem we have develo...
متن کاملOptimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
The emergence of antibody-drug conjugates (ADC), such as brentuximab vedotin and ado-trastuzumab emtansine, has led to increased efforts to identify new payloads and develop improved drug-linker technologies. Most antibody payloads impart significant hydrophobicity to the ADC, resulting in accelerated plasma clearance and suboptimal in vivo activity, particularly for conjugates with high drug-t...
متن کامل